Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBITDA (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed EBITDA for 16 consecutive years, with -$40.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 298.18% to -$40.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$150.1 million through Dec 2025, down 277.04% year-over-year, with the annual reading at -$150.1 million for FY2025, 277.04% down from the prior year.
  • EBITDA hit -$40.0 million in Q4 2025 for Vanda Pharmaceuticals, down from -$31.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $12.7 million in Q2 2021 to a low of -$40.8 million in Q1 2025.
  • Historically, EBITDA has averaged -$7.6 million across 5 years, with a median of -$6.4 million in 2023.
  • Biggest five-year swings in EBITDA: soared 4628.32% in 2021 and later crashed 493.42% in 2024.
  • Year by year, EBITDA stood at $9.0 million in 2021, then fell by 23.15% to $6.9 million in 2022, then crashed by 200.19% to -$6.9 million in 2023, then plummeted by 45.58% to -$10.1 million in 2024, then plummeted by 298.18% to -$40.0 million in 2025.
  • Business Quant data shows EBITDA for VNDA at -$40.0 million in Q4 2025, -$31.0 million in Q3 2025, and -$38.2 million in Q2 2025.